Lutetium-177 Dotatate Peptide Receptor Radionuclide Therapy in metastatic pheochromocytoma and paraganglioma: Experience in our center

被引：0
作者：
Negre, M. [1 ]
Guardeno, R. [1 ]
Biarnes, J. [1 ]
Recasens, M. [1 ]
Rubio, A. [1 ]
机构：
[1] Hosp Univ Girona Dr Josep Trueta, Girona, Spain
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2024年 / 36卷
关键词：
prrt; 177lu-dotatate; metastatic paraganglioma; metastatic pheochromocytoma;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H13
引用
收藏
页码：210 / 210
页数：1
相关论文
共 50 条
  • [21] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
    Bodei, Lisa
    Cremonesi, Marta
    Grana, Chiara M.
    Fazio, Nicola
    Iodice, Simona
    Baio, Silvia M.
    Bartolomei, Mirco
    Lombardo, Dario
    Ferrari, Mahila E.
    Sansovini, Maddalena
    Chinol, Marco
    Paganelli, Giovanni
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (12) : 2125 - 2135
  • [22] Gallbladder Visualization in Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE A Potential Mimicker of Hepatic Metastases
    Diekmann, Johanna
    Werner, Rudolf A.
    Ross, Tobias L.
    Derlin, Thorsten
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (12) : E521 - E522
  • [23] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
    Lisa Bodei
    Marta Cremonesi
    Chiara M. Grana
    Nicola Fazio
    Simona Iodice
    Silvia M. Baio
    Mirco Bartolomei
    Dario Lombardo
    Mahila E. Ferrari
    Maddalena Sansovini
    Marco Chinol
    Giovanni Paganelli
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 2125 - 2135
  • [24] Polish Multicenter Experience with Tandem Peptide Receptor Radionuclide Therapy Using 90Y/177Lu-DOTATATE in Neuroendocrine Tumors
    Kunikowska, J.
    Zemczak, A.
    Kolodziej, M.
    Gut, P.
    Lon, I
    Pawlak, D.
    Mikolajczak, R.
    Kaminski, G.
    Ruchala, M.
    Kos-Kudla, B.
    Krolicki, L.
    NEUROENDOCRINOLOGY, 2019, 108 : 216 - 216
  • [25] Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)
    Kong, G.
    Grozinsky-Glasberg, S.
    Callahan, J.
    Hofman, M.
    Meirovitz, A.
    Maimon, O.
    Pattison, D.
    Gross, D.
    Hicks, R.
    NEUROENDOCRINOLOGY, 2017, 105 : 249 - 249
  • [26] Peptide Receptor Radionuclide Therapy Using 177Lu and 90Y-DOTATATE in Metastatic Treatment-Refractory Medullary Thyroid Cancer
    Puranik, A.
    Baum, R. P.
    Kulkarni, H.
    Singh, A.
    Rangarajan, V
    Agrawal, A.
    Shah, S.
    Purandare, N.
    NEUROENDOCRINOLOGY, 2019, 108 : 228 - 228
  • [27] Favorable Response After Only One Cycle of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Metastatic Merkel Cell Carcinoma
    Moghadam, Soroush Zarehparvar
    Divband, Ghasemali
    Shakeri, Sara
    Aryana, Kamran
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (08) : 650 - 652
  • [28] Comparison of 68Ga-DOTATATE PET/CT for Assessment of Response to Peptide Receptor Radionuclide Therapy after 2 and 4 Cycles of 177Lu-DOTATATE: Preliminary Single Academic Center Experience
    Song, H.
    Kunz, P.
    Fisher, G.
    Franc, B.
    Moradi, F.
    Davidz, G.
    Iag, A.
    Aparic, Mari C.
    NEUROENDOCRINOLOGY, 2020, 110 : 273 - 273
  • [29] Comparison of commercial dosimetric software platforms in patients treated with 177Lu-DOTATATE for peptide receptor radionuclide therapy
    Mora-Ramirez, Erick
    Santoro, Lore
    Cassol, Emmanuelle
    Ocampo-Ramos, Juan C.
    Clayton, Naomi
    Kayal, Gunjan
    Chouaf, Soufiane
    Trauchessec, Dorian
    Pouget, Jean-Pierre
    Kotzki, Pierre-Olivier
    Deshayes, Emmanuel
    Bardies, Manuel
    MEDICAL PHYSICS, 2020, 47 (09) : 4602 - 4615
  • [30] Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy
    Makis, William
    McCann, Karey
    Riauka, Terence A.
    McEwan, Alexander J. B.
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) : 877 - 879
12345